Eva Furstova

Eva Furstova

Auto-generated profile, based on publicly available information

Eva Furstova

Department of Paediatrics, First Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2020 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
ARAnabela Santo Ramalho
Anabela Santo Ramalho
EFEva Fürstová
Eva Fürstová
AVAnnelotte M. Vonk
Annelotte M. Vonk
MFMarc Ferrante
Marc Ferrante
CVCatherine Verfaillie
Catherine Verfaillie
KBKris De Boeck
Kris De Boeck
Rationale: Given the vast number of cystic fibrosis transmembrane conductance regulator (CFTR) mutations, biomarkers predicting benefit from CFTR modulator therapies are needed for subjects with cystic fibrosis (CF).Objectives: To study CFTR function in organoids of subjects with common and rareCFTRmutations and evaluate correlations between CFTR function and clinical data.Methods: Intestinal organoids were grown from rectal biopsies in a cohort of 97 subjects with CF. Residual CFTR function was measured by quantifying organoid swelling induced by forskolin and response to modulators by quantifying organoid swelling induced by CFTR correctors, potentiator and their combination. Organoid data were correlated with clinical data from the literature.Results: Across 28 genotypes, residual CFTR function correlated (r2=0.87) with sweat chloride values. When studying the same genotypes, CFTR function rescue by CFTR modulators in organoids correlated tightly with mean improvement in lung function (r2=0.90) and sweat chloride (r2=0.95) reported in clinical trials. We identified candidate genotypes for modulator therapy, such as E92K, Q237E, R334W and L159S. Based on organoid results, two subjects started modulator treatment: one homozygous for complex allele Q359K_T360K, and the second with mutation E60K. Both subjects had major clinical benefit.Conclusions: Measurements of residual CFTR function and rescue of function by CFTR modulators in intestinal organoids correlate closely with clinical data. Our results for reference genotypes concur with previous results. CFTR function measured in organoids can be used to guide precision medicine in patients with CF, positioning organoids as a potentialin vitromodel to bring treatment to patients carrying rareCFTRmutations.

1 March 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
EFEva Furstova
Eva Furstova
TDTereza Dousova
Tereza Dousova
JBJakub Beranek
Jakub Beranek
MLMalgorzata Libik
Malgorzata Libik
LFLibor Fila
Libor Fila
PDPavel Drevinek
Pavel Drevinek

14 March 2024 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
EFEva Furstova
Eva Furstova
PDPavel Drevinek
Pavel Drevinek
SNStepanka Novotna
Stepanka Novotna
MLMalgorzata Libik
Malgorzata Libik
KBKlara Benesova
Klara Benesova
TDTereza Dousova
Tereza Dousova

14 September 2024 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
OCOndrej Cinek
Ondrej Cinek
EFEva Furstova
Eva Furstova
SNStepanka Novotna
Stepanka Novotna
KHKlara Hubackova
Klara Hubackova
TDTereza Dousova
Tereza Dousova
PDPavel Drevinek
Pavel Drevinek

27 February 2026 in Respiratory Medicine
Verified
Journal Article
Open access
LBLucie Borek-Dohalska
Lucie Borek-Dohalska
MMMartin Modrák
Martin Modrák
SNStepanka Novotna
Stepanka Novotna
EFEva Furstova
Eva Furstova
ZVZofia Varenyiova
Zofia Varenyiova
PDPavel Drevinek
Pavel Drevinek
The triple combination of vanzacaftor/tezacaftor/deutivacaftor (VAN/TEZ/D-IVA) is a new alternative to the established therapy with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis (pwCF). While both therapies show similar effects on lung function, VAN/TEZ/D-IVA further reduces sweat chloride concentrations. We aimed to explore the potential of triple combination VAN/TEZ/IVA to enhance the CFTR function in vitro. Primary nasal epithelial cells (HNECs) and patient-derived intestinal organoids (PDIOs), both obtained from the same 12 F508del/F508del pwCF, were pretreated with ELX/TEZ, VAN/TEZ or left untreated. The response to the CFTR modulators was assessed using the transepithelial short-circuit current (ISC) measured by the Ussing chamber method after the sequential addition of amiloride, forskolin (Fsk) with 3-isobutyl-1-methylxanthine (IBMX), IVA, CFTRinh-172 and ATP to HNECs from pwCF and 10 healthy donors (WT). ΔCFTRinh-172 ISC was used for assessment of CFTR activity (expressed as percentage of WT activity). The response of PDIOs to the CFTR modulators was tested using the forskolin induced swelling (FIS) assay. CFTR activity was expressed as area under the curve (AUC). Significant differences in CFTR-mediated chloride ISC were observed between untreated, ELX/TEZ-pretreated and VAN/TEZ-pretreated HNECs from pwCF. CFTR function was restored to 45% of WT levels with ELX/TEZ/IVA and to 67% with VAN/TEZ/IVA. Using the FIS assay, effects of both triple combinations on swelling of PDIOs were comparable. VAN/TEZ/IVA demonstrated superior CFTR functional rescue in F508del/F508del HNECs than ELX/TEZ/IVA. These findings highlight the greater discriminatory power of airway epithelial electrophysiology compared to PDIOs when comparing highly effective CFTR modulator therapies.

20 April 2026 in European Journal of Pediatrics
Verified
Journal Article
Open access
ĽBĽuboš Bača
Ľuboš Bača
EFEva Fürstová
Eva Fürstová
MPMonika Pecková
Monika Pecková
KKKateřIna Kotíková
KateřIna Kotíková
JDJan David
Jan David
PKPatrik Konopásek
Patrik Konopásek
Cough and cold medications (CCMs) are widely used in paediatric practice despite limited evidence of efficacy and concerns regarding safety in young children. This study aimed to evaluate Czech paediatricians’ knowledge, attitudes, and recommendation practices related to CCMs and to identify factors associated with inappropriate use in children under 6 years of age. An anonymous questionnaire-based survey was distributed online to hospital paediatricians and general practitioners for children across the Czech Republic. The survey assessed demographic characteristics, patterns of CCMs use, knowledge of efficacy and safety, awareness of international recommendations, and attitudes toward potential restrictions and educational interventions. Associations were analysed using descriptive statistics, logistic regression, and Fisher’s exact test where appropriate. Of 266 respondents, 74.1% reported using CCMs in children under 6 years and 40.6% in children under 2 years. Recommendation practices were not associated with age or postgraduate training but varied significantly by region and medical school attended. Reliance on international literature was associated with the lowest use of CCMs, whereas reliance on local sources or older colleagues predicted higher use. Lack of awareness of the unproven efficacy of CCMs, as well as recommendations from the American Academy of Pediatrics and Health Canada, were the strongest predictors of inappropriate recommendations. While knowledge of the Medicines and Healthcare products Regulatory Agency recommendation also showed association with a good recommendation practice, the association was not significant in the multivariable model. Conclusion:  Despite robust international guidance, CCMs remain commonly used in Czech paediatrics. Knowledge gaps, entrenched habits, and reliance on outdated information sources contribute to inappropriate use. Targeted educational initiatives and harmonised national guidelines are needed to improve practice. What is Known:● CCMs remain widely used in paediatrics despite limited efficacy and safety concerns in young children. ● International recommendations, including those from the AAP and Health Canada, advise against CCMs use in children under 6 years. What is New:● In the Czech Republic, CCMs are used by 74% of paediatricians in children < 6 years and 41% in children < 2 years. ● CCMs recommendation practices vary by region and medical school, but not by age or training level. Higher inappropriate use is associated with reliance on local sources and older colleagues.